Which has preferable earnings and valuation, ZNTL or HELP?

Cybin is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.95 N/A Cybin N/A N/A -$148M -$3.02 N/A

Is ZNTL or HELP more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Cybin N/A -71.78% -64.81%

Does the media favor ZNTL or HELP?

In the previous week, Cybin had 18 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 19 mentions for Cybin and 1 mentions for Zentalis Pharmaceuticals. Cybin's average media sentiment score of 0.46 beat Zentalis Pharmaceuticals' score of 0.31 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 3 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ZNTL or SGP?

Spyglass Pharma is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.95 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is ZNTL or SGP more profitable?

Spyglass Pharma's return on equity of -62.40% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Spyglass Pharma N/A -62.40% -24.83%

Does the media favor ZNTL or SGP?

In the previous week, Spyglass Pharma had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Spyglass Pharma and 1 mentions for Zentalis Pharmaceuticals. Spyglass Pharma's average media sentiment score of 0.46 beat Zentalis Pharmaceuticals' score of 0.31 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ZNTL or ARDX?

In the previous week, Ardelyx had 20 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 21 mentions for Ardelyx and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.31 beat Ardelyx's score of -0.03 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 2 Very Positive mention(s) 1 Positive mention(s) 15 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to TBPH or ZNTL?

In the previous week, Theravance Biopharma had 9 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 10 mentions for Theravance Biopharma and 1 mentions for Zentalis Pharmaceuticals. Theravance Biopharma's average media sentiment score of 0.39 beat Zentalis Pharmaceuticals' score of 0.31 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ZNTL or IVA?

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.95 N/A Inventiva $4.48M 159.85 -$400.67M N/A N/A

Is ZNTL or IVA more profitable?

Inventiva's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Inventiva N/A N/A N/A

Does the media favor ZNTL or IVA?

In the previous week, Inventiva had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.31 beat Inventiva's score of 0.24 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Zentalis Pharmaceuticals (ZNTL) Competitors

$2.87 -0.21 (-6.82%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.84 -0.04 (-1.22%)

As of 05:07 AM Eastern

Compare

ZNTL vs. HELP, SGP, ARDX, TBPH, and IVA

Should you buy Zentalis Pharmaceuticals stock or one of its competitors? Zentalis Pharmaceuticals's main competitors and comparable companies include Cybin (HELP), Spyglass Pharma (SGP), Ardelyx (ARDX), Theravance Biopharma (TBPH), and Inventiva (IVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zentalis Pharmaceuticals compare to Cybin?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Cybin has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

17.9% of Cybin shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cybin is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Zentalis Pharmaceuticals' return on equity of -70.18% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Cybin	N/A	-71.78%	-64.81%

Zentalis Pharmaceuticals presently has a consensus target price of $6.75, suggesting a potential upside of 135.19%. Cybin has a consensus target price of $46.33, suggesting a potential upside of 255.86%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Cybin had 18 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 19 mentions for Cybin and 1 mentions for Zentalis Pharmaceuticals. Cybin's average media sentiment score of 0.46 beat Zentalis Pharmaceuticals' score of 0.31 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	3 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Cybin beats Zentalis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Spyglass Pharma?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

In the previous week, Spyglass Pharma had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Spyglass Pharma and 1 mentions for Zentalis Pharmaceuticals. Spyglass Pharma's average media sentiment score of 0.46 beat Zentalis Pharmaceuticals' score of 0.31 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyglass Pharma is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Spyglass Pharma's return on equity of -62.40% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Spyglass Pharma	N/A	-62.40%	-24.83%

Zentalis Pharmaceuticals currently has a consensus price target of $6.75, suggesting a potential upside of 135.19%. Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 56.25%. Given Zentalis Pharmaceuticals' higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Spyglass Pharma beats Zentalis Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Ardelyx?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Ardelyx has higher revenue and earnings than Zentalis Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A
Ardelyx	$407.32M	2.13	-$61.60M	-$0.22	N/A

58.9% of Ardelyx shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zentalis Pharmaceuticals currently has a consensus price target of $6.75, indicating a potential upside of 135.19%. Ardelyx has a consensus price target of $13.90, indicating a potential upside of 299.43%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Ardelyx	-12.35%	-36.00%	-10.77%

In the previous week, Ardelyx had 20 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 21 mentions for Ardelyx and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.31 beat Ardelyx's score of -0.03 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	2 Very Positive mention(s)	1 Positive mention(s)	15 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zentalis Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Summary

Ardelyx beats Zentalis Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Theravance Biopharma has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.23	$105.89M	$1.01	16.86
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A

In the previous week, Theravance Biopharma had 9 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 10 mentions for Theravance Biopharma and 1 mentions for Zentalis Pharmaceuticals. Theravance Biopharma's average media sentiment score of 0.39 beat Zentalis Pharmaceuticals' score of 0.31 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Theravance Biopharma shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Theravance Biopharma presently has a consensus target price of $19.40, indicating a potential upside of 13.92%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 135.19%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Theravance Biopharma has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Theravance Biopharma has a net margin of 51.58% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Theravance Biopharma's return on equity of -0.77% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Summary

Theravance Biopharma beats Zentalis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Inventiva?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, Inventiva had 2 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 0.31 beat Inventiva's score of 0.24 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zentalis Pharmaceuticals presently has a consensus target price of $6.75, suggesting a potential upside of 135.19%. Inventiva has a consensus target price of $15.75, suggesting a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

19.1% of Inventiva shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A
Inventiva	$4.48M	159.85	-$400.67M	N/A	N/A

Zentalis Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Inventiva's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Inventiva	N/A	N/A	N/A

Summary

Inventiva beats Zentalis Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$220.75M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-1.47	792.28	274.08	25.69
Price / Sales	N/A	862.22	638.21	78.99
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.96	10.59	10.47	6.32
Net Income	-$137.06M	$2.81B	$3.49B	$359.73M
7 Day Performance	-6.82%	-0.11%	-0.67%	0.17%
1 Month Performance	-23.67%	-1.34%	-3.17%	-3.27%
1 Year Performance	88.82%	2.86%	15.14%	5.58%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	3.7345 of 5 stars	$2.87 -6.8%	$6.75 +135.2%	+91.3%	$220.75M	N/A	N/A	106	Positive News
HELP Cybin	4.6234 of 5 stars	$13.61 +4.9%	$48.60 +257.1%	N/A	$980.68M	N/A	N/A	100	Insider Trade
SGP Spyglass Pharma	2.5068 of 5 stars	$28.66 +4.1%	$44.00 +53.5%	N/A	$920.09M	N/A	N/A	65
ARDX Ardelyx	2.6701 of 5 stars	$3.52 -1.7%	$13.90 +294.9%	-43.4%	$892.09M	$407.32M	N/A	489	Trending News
TBPH Theravance Biopharma	3.0802 of 5 stars	$17.03 +0.1%	$19.40 +13.9%	+21.0%	$883.14M	$107.46M	16.86	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. HELP, SGP, ARDX, TBPH, and IVA

How does Zentalis Pharmaceuticals compare to Cybin?

Summary

How does Zentalis Pharmaceuticals compare to Spyglass Pharma?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Summary

How does Zentalis Pharmaceuticals compare to Theravance Biopharma?

Summary

How does Zentalis Pharmaceuticals compare to Inventiva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. HELP, SGP, ARDX, TBPH, and IVA

How does Zentalis Pharmaceuticals compare to Cybin?

Which has more volatility and risk, ZNTL or HELP?

Do insiders & institutionals have more ownership in ZNTL or HELP?

Which has preferable earnings and valuation, ZNTL or HELP?

Is ZNTL or HELP more profitable?

Do analysts rate ZNTL or HELP?

Does the media favor ZNTL or HELP?

Summary

How does Zentalis Pharmaceuticals compare to Spyglass Pharma?

Does the media favor ZNTL or SGP?

Which has preferable valuation and earnings, ZNTL or SGP?

Is ZNTL or SGP more profitable?

Do analysts prefer ZNTL or SGP?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Which has stronger earnings & valuation, ZNTL or ARDX?

Do institutionals and insiders have more ownership in ZNTL or ARDX?

Do analysts recommend ZNTL or ARDX?

Is ZNTL or ARDX more profitable?

Does the media favor ZNTL or ARDX?

Which has more risk & volatility, ZNTL or ARDX?

Summary

How does Zentalis Pharmaceuticals compare to Theravance Biopharma?

Which has stronger valuation & earnings, TBPH or ZNTL?

Does the media refer more to TBPH or ZNTL?

Do institutionals & insiders believe in TBPH or ZNTL?

Do analysts recommend TBPH or ZNTL?

Which has more risk and volatility, TBPH or ZNTL?

Is TBPH or ZNTL more profitable?

Summary

How does Zentalis Pharmaceuticals compare to Inventiva?

Does the media favor ZNTL or IVA?

Do analysts recommend ZNTL or IVA?

Do institutionals and insiders hold more shares of ZNTL or IVA?

Which has preferable valuation & earnings, ZNTL or IVA?

Which has more volatility and risk, ZNTL or IVA?

Is ZNTL or IVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools